Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ACCESS Act back in House (and Senate)

Executive Summary

Sen. Sam Brownback, R-Kan., and Rep. Diane Watson, D-Calif., re-introduced the Access, Compassion, Care and Ethics for Seriously Ill Patients Act (ACCESS) May 21. The bill, initially introduced in 2005, would expand investigational treatment access for terminally ill patients who have exhausted other medical options (1"The Pink Sheet," Aug. 27, 2007, p. 9)

You may also be interested in...



Abigail Alliance Looks For Paths Forward After Court Blocks Drug Access Suit

After losing at the appeals court in its bid to overturn FDA's regulations on access to experimental therapies, the Abigail Alliance is considering several legal options. The group is preparing to ask the Supreme Court to consider the case, but if that bid fails, alternatives include congressional action and bringing another case in a different jurisdiction

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel